Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer

Introduction Triple-negative breast cancer (TNBC) is associated with lack of expression of estrogen and progesterone receptors and HER2 and is the subgroup of breast cancers with the worst prognosis. Osteopontin is a phosphorylated glycoprotein whose overexpression may occur in pathological states s...

全面介紹

書目詳細資料
發表在:Archives of Medical Science
Main Authors: Magdalena Niedolistek, Marta M. Fudalej, Aleksandra Sobiborowicz, Anna Liszcz, Michał P. Budzik, Maciej Sobieraj, Janusz Patera, Aleksandra Czerw, Urszula Religioni, Maria Sobol, Andrzej Deptała, Anna M. Badowska-Kozakiewicz
格式: Article
語言:英语
出版: Termedia Publishing House 2020-04-01
主題:
在線閱讀:https://www.archivesofmedicalscience.com/Immunohistochemical-evaluation-of-osteopontin-expression-in-triple-negative-breast,114841,0,2.html
_version_ 1850282881389166592
author Magdalena Niedolistek
Marta M. Fudalej
Aleksandra Sobiborowicz
Anna Liszcz
Michał P. Budzik
Maciej Sobieraj
Janusz Patera
Aleksandra Czerw
Urszula Religioni
Maria Sobol
Andrzej Deptała
Anna M. Badowska-Kozakiewicz
author_facet Magdalena Niedolistek
Marta M. Fudalej
Aleksandra Sobiborowicz
Anna Liszcz
Michał P. Budzik
Maciej Sobieraj
Janusz Patera
Aleksandra Czerw
Urszula Religioni
Maria Sobol
Andrzej Deptała
Anna M. Badowska-Kozakiewicz
author_sort Magdalena Niedolistek
collection DOAJ
container_title Archives of Medical Science
description Introduction Triple-negative breast cancer (TNBC) is associated with lack of expression of estrogen and progesterone receptors and HER2 and is the subgroup of breast cancers with the worst prognosis. Osteopontin is a phosphorylated glycoprotein whose overexpression may occur in pathological states such as cancers. The main purpose of our study was to evaluate the immunohistochemical expression of osteopontin in connection with the analysis of recognized clinical and pathological prognostic factors in primary sites of TNBC with and without lymph node metastases. Material and methods The immunohistochemical evaluation of osteopontin expression in 35 women with TNBC, chosen from a group of 726 patients, was performed. The material came from the excisional biopsies of primary breast cancers and total mastectomies. Results All patients showed expression of osteopontin, in most cases the expression of osteopontin rated at [+] (57.1%) and [++] (42.9%). Our study analyzed the relationship between the expression of osteopontin and traditional prognostic markers, such as the tumor grade, size, and lymph node involvement. We found a strong relationship only between the expression of osteopontin and the presence of lymph node metastases (p ≤ 0.0001). 93% of patients for whom the expression of osteopontin was determined at [++] had metastasis to lymph nodes and, for comparison, only 15% of women for whom the expression of osteopontin was rated at [+] showed the presence of metastases in the lymphatic nodes. Conclusions There is a correlation between osteopontin expression and the presence of lymph node metastases in TNBC, suggesting that osteopontin plays an important role in the invasiveness of TNBC.
format Article
id doaj-art-e6f8aebc8d514f2db4953665e82ee295
institution Directory of Open Access Journals
issn 1734-1922
1896-9151
language English
publishDate 2020-04-01
publisher Termedia Publishing House
record_format Article
spelling doaj-art-e6f8aebc8d514f2db4953665e82ee2952025-08-19T23:38:27ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512020-04-0120243644310.5114/aoms.2020.93695114841Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancerMagdalena Niedolistek0Marta M. Fudalej1Aleksandra Sobiborowicz2Anna Liszcz3Michał P. Budzik4Maciej Sobieraj5Janusz Patera6Aleksandra Czerw7Urszula Religioni8Maria Sobol9Andrzej Deptała10Anna M. Badowska-Kozakiewicz11Students’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandDepartment of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandDepartment of Pathomorphology, Military Institute of Health Services, Warsaw, PolandDepartment of Health Economics and Medical Law, Medical University of Warsaw, Warsaw, PolandCollegium of Business Administration, Warsaw School of Economics, Warsaw, PolandDepartment of Biophysics and Human Physiology, Medical University of Warsaw, PolandDepartment of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandDepartment of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandIntroduction Triple-negative breast cancer (TNBC) is associated with lack of expression of estrogen and progesterone receptors and HER2 and is the subgroup of breast cancers with the worst prognosis. Osteopontin is a phosphorylated glycoprotein whose overexpression may occur in pathological states such as cancers. The main purpose of our study was to evaluate the immunohistochemical expression of osteopontin in connection with the analysis of recognized clinical and pathological prognostic factors in primary sites of TNBC with and without lymph node metastases. Material and methods The immunohistochemical evaluation of osteopontin expression in 35 women with TNBC, chosen from a group of 726 patients, was performed. The material came from the excisional biopsies of primary breast cancers and total mastectomies. Results All patients showed expression of osteopontin, in most cases the expression of osteopontin rated at [+] (57.1%) and [++] (42.9%). Our study analyzed the relationship between the expression of osteopontin and traditional prognostic markers, such as the tumor grade, size, and lymph node involvement. We found a strong relationship only between the expression of osteopontin and the presence of lymph node metastases (p ≤ 0.0001). 93% of patients for whom the expression of osteopontin was determined at [++] had metastasis to lymph nodes and, for comparison, only 15% of women for whom the expression of osteopontin was rated at [+] showed the presence of metastases in the lymphatic nodes. Conclusions There is a correlation between osteopontin expression and the presence of lymph node metastases in TNBC, suggesting that osteopontin plays an important role in the invasiveness of TNBC.https://www.archivesofmedicalscience.com/Immunohistochemical-evaluation-of-osteopontin-expression-in-triple-negative-breast,114841,0,2.htmlimmunohistochemistryosteopontintriple-negative breast cancer
spellingShingle Magdalena Niedolistek
Marta M. Fudalej
Aleksandra Sobiborowicz
Anna Liszcz
Michał P. Budzik
Maciej Sobieraj
Janusz Patera
Aleksandra Czerw
Urszula Religioni
Maria Sobol
Andrzej Deptała
Anna M. Badowska-Kozakiewicz
Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
immunohistochemistry
osteopontin
triple-negative breast cancer
title Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
title_full Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
title_fullStr Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
title_full_unstemmed Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
title_short Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
title_sort immunohistochemical evaluation of osteopontin expression in triple negative breast cancer
topic immunohistochemistry
osteopontin
triple-negative breast cancer
url https://www.archivesofmedicalscience.com/Immunohistochemical-evaluation-of-osteopontin-expression-in-triple-negative-breast,114841,0,2.html
work_keys_str_mv AT magdalenaniedolistek immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT martamfudalej immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT aleksandrasobiborowicz immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT annaliszcz immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT michałpbudzik immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT maciejsobieraj immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT januszpatera immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT aleksandraczerw immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT urszulareligioni immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT mariasobol immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT andrzejdeptała immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer
AT annambadowskakozakiewicz immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer